Biomea Fusion Logo PNG
The Biomea Fusion logo conveys a thoughtful approach to treating complex diseases, combining science and care. The company is developing drugs that account for the specifics of metabolic and oncogenic processes, using the FUSION™ platform to advance new medical solutions.
Biomea Fusion was founded in Redwood City, California, in August 2017 by Thomas Butler and Ramses Erdtmann, former colleagues at Pharmacyclics. The company developed the FUSION System, a platform for designing covalent small molecules that form permanent bonds with selected protein targets.
Its first major candidate was BMF-219, a covalent inhibitor of menin, initially studied for acute leukemia and KRAS-mutated solid tumors. In December 2020, Biomea raised about $56 million in Series A funding. The company went public on April 16, 2021, raising roughly $167 million under the NASDAQ ticker BMEA. The company later opened the COVALENT-101 oncology trial and advanced BMF-500, an FLT3 inhibitor for acute leukemia. Its covalent approach differed from programs at Syndax Pharmaceuticals and Kura Oncology.
Biomea then expanded BMF-219 into type 2 diabetes through the Phase 2 COVALENT-111 study. In June 2024, the FDA placed the program on clinical hold, causing the company’s shares to fall by over 55% in one day. The restriction was lifted in December 2024, when Biomea reported a statistically significant reduction in HbA1c among the target patient group.
In January 2025, the company ended its oncology programs and shifted entirely toward diabetes and obesity. BMF-500 was discontinued after dose escalation, about 35% of employees were laid off, and operations were consolidated. In March 2025, Butler stepped down as CEO and Mick Hitchcock took the role on an interim basis.
Meaning and History
What is Biomea Fusion?
The company develops drugs to fight cancer and other serious diseases. Its specialists create drugs that selectively affect tumor cells while minimally affecting healthy tissues. One of the key products is a drug with promising results in treating stomach cancer and leukemia. The team comprises experts in medicine, chemistry, and molecular biology focused on creating new treatments and improving existing solutions.
2017 – today
The Biomea Fusion logo suggests a connection to biology, medicine, and modern technology. The company is American and focuses on developing medications through molecular biology research. That’s why they chose the name “Biomea,” a combination of “Bio” (biology) and “Mea” (to measure). The name reflects the company’s work with living systems, the precision of its research, and the technology it uses to treat serious diseases.
The main symbol resembles a cell. On the left, two smooth, wavy lines form a double oval resembling a living cell membrane. In the center, a small circle represents the cell nucleus. Together, these elements create a clear and simple representation of a living organism at the smallest level. The emblem’s idea is straightforward: visually connecting science, living cells, and the human body. At the cellular level, the company seeks new approaches to treating cancer and metabolic disorders.
Next to the emblem is the brand name. All the letters are lowercase, simple, and rounded, giving a soft and calm appearance. The font is smooth, with no sharp angles or serifs, keeping it minimalistic. An interesting detail is that the dot above the “i” exactly matches the nucleus in the cell illustration on the left, linking the graphic and text together.
Below “biomea,” the word “FUSION” is written in a completely different style, a stricter, uppercase font with thin lines. It adds a sense of technology and modernity. The word “fusion” means “merging” or “combining,” which perfectly represents the company’s mission: bringing together scientific knowledge from different fields to create something new and beneficial for medicine and human health. The company even has a specialized platform called FUSION™ that helps develop new medications.
The chosen color is a bright and rich green. Green represents health, nature, and life. It looks fresh, scientific, and optimistic, reinforcing the company’s focus on biotechnology and medicine.
The result is a modern, clean, and meaningful logo that reflects the spirit of a company working in a complex and crucial field. The entire story behind the cell, science, and green color visually explains what Biomea Fusion does and how it aims to transform approaches to treating serious diseases.